Form D · Pharmaceuticals

Millendo Therapeutics, Inc.

Ann Arbor, MI · CIK 0001547547

Offering snapshot reported Dec 28, 2017 · SEC filing

Reported sold
$50M
Offering amount: $59.1M
Investors reported
14
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 19, 2017
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 28, 2017Initial$50,043,201No comparison14SEC filing
Jan 4, 2016Initial$47,697,172No comparison21SEC filing
Feb 26, 2013Amendment$8,522,872$5,016,461vs Sep 27, 20127SEC filing
Sep 27, 2012Amendment$3,506,411$2,000,000vs Aug 3, 20126SEC filing
Aug 3, 2012Initial$1,506,411No comparison4SEC filing
Apr 23, 2012Initial$250,000No comparison1SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
Yes
Business combination
Yes
Sales commissions
$0
Finders' fees
$0
Form D file number
021-301902

Source: Form D, filed Dec 28, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Thierry Abribat Director
Jeffery Brinza Executive
Carol Gallagher Director
William Harrington Director
Mary Lynne Hedley Director
James Hindman Director
Raili Kerppola Executive
Pharis Mohideen Executive
Carole Neuchterlein Director
Julia Owens Director, Executive
Andrew J. Schwab Director
Christopher Seiter Executive
James Topper Director
Randall Whitcomb Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
301 North Main Street Suite 100
Ann Arbor, MI, 48104